Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial.

CONCLUSIONS: The effective prediction of the pathological response to NAC regimens in locally advanced GC using biomarkers identified from endoscopic biopsy specimens indicates the possibility of personalizing NAC based on biomarker analysis. PMID: 32774771 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/32774771?dopt=Abstract

Source: Oncotarget - August 13, 2020 Category: Cancer & Oncology Tags: Oncotarget Source Type: research